Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04027972 · ClinicalTrials.gov registry record · Early Phase 1
Pharmacokinetics of Neostigmine and Glycopyrrolate
A Early Phase 1 study, sponsored by James J. Peters Veterans Affairs Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 13
- Enrollment target
NCT04027972: Completed Early Phase 1 study, sponsored by James J. Peters Veterans Affairs Medical Center.
NCT04027972 is a Early Phase 1 study that has completed, run by James J. Peters Veterans Affairs Medical Center. The registered enrollment target is 13 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04027972, a Early Phase 1 study, has completed, sponsored by James J. Peters Veterans Affairs Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
A group of 6 able-bodied healthy volunteers will receive Neostigmine (NEO) and Glycopyrrolate (GLY) intravenously and via 2 methods of Iontophoresis (ION): one-patch and two-patch administration, with subsequent blood draws over 1 hour in order to measure the pharmacokinetic behavior of the drugs in-vivo.
Primary Outcome
Measurement of serum concentration of Neostigmine and of Glycopyrrolate to determine pharmacokinetic profiles
Interventions
- DRUG Combination of Neostigmine and Glycopyrrolate
- DEVICE I-Box by Dynatronics
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-03-09 |
| Est. Completion | 2022-12-20 |
| Phase | Early Phase 1 |
What the finished NCT04027972 record still lists
NCT04027972 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 2 interventions - of which Combination of Neostigmine and Glycopyrrolate is the first listed.
NCT04027972 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04027972 about?
NCT04027972 is a clinical study titled "Pharmacokinetics of Neostigmine and Glycopyrrolate". A group of 6 able-bodied healthy volunteers will receive Neostigmine (NEO) and Glycopyrrolate (GLY) intravenously and via 2 methods of Iontophoresis (ION): one-patch and two-patch administration, with subsequent blood draws over 1 hour in order to measure the pharmacokinetic behavior of the drugs in...
What is the current status of trial NCT04027972?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 13 participants. The study started on 2020-03-09. Estimated completion is 2022-12-20.
What interventions are being tested in trial NCT04027972?
The interventions under investigation include: Combination of Neostigmine and Glycopyrrolate (DRUG), I-Box by Dynatronics (DEVICE).
Who is sponsoring clinical trial NCT04027972?
This trial is sponsored by James J. Peters Veterans Affairs Medical Center, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04027972's enrollment target sits among peer trials
13 1504th of 2000 higher than 472 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI